IL17A and fungal infectious disease: However, long-term inhibition of IL-6– or IL-17A–induced proinflammatory effects by Ab drugs may hamper the immunity of RA patients and increase the risk of adverse events such as serious tuberculosis infection [42] or fungal infection [43].